查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1996478

獸用抗菌藥物敏感性檢測市場：依檢測類型、動物類型、病原體類型、檢體類型、產品類型和最終用戶分類－2026-2032年全球市場預測

Veterinary Antimicrobial Susceptibility Testing Market by Test Type, Animal Type, Pathogen Type, Sample Type, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸用抗菌藥物敏感性測試市場價值將達到 1.2333 億美元，到 2026 年將成長至 1.3771 億美元，到 2032 年將達到 2.3188 億美元，年複合成長率為 9.43%。

主要市場統計數據
基準年 2025 1.2333億美元
預計年份：2026年 1.3771億美元
預測年份：2032年 2.3188億美元
複合年成長率 (%) 9.43%

在臨床實踐、實驗室操作以及「同一健康」的更廣泛要求的背景下，明確獸醫抗菌藥物敏感性測試的作用並指導及時和負責任的干涉措施至關重要。

動物健康領域抗生素抗藥性的日益嚴重，迫切需要以實證醫學為基礎，明確診斷檢測在維持療效、保護動物和公眾健康方面的作用。獸用抗生素敏感性檢測是臨床決策、監測和法律規範的交匯點，其有效實施會影響治療效果、合理使用抗生素以及新抗藥性機制的發現。隨著診斷能力的提升，實驗室和臨床醫生必須採用能夠在臨床適用的時限內提供可靠且可重複結果的工作流程和技術。

技術創新、監管進步和數位融合如何重塑獸醫易感性檢測並加速臨床和監測能力的發展？

獸醫抗菌藥物敏感性檢測的變革性變化反映了技術創新、不斷變化的監管要求和不斷變化的臨床需求，這些因素共同重塑了診斷管道。自動化系統提高了處理能力和標準化程度，使實驗室能夠在擴大業務規模的同時降低敏感性測定結果的變異性。同時，快速分子技術和新一代定序技術增強了檢測抗藥性決定因素和追蹤傳播的能力，從而加強了監測能力，並有助於制定有針對性的干涉措施。

評估 2025 年關稅調整對診斷設備、耗材和實驗室供應鏈韌性的營運和採購影響。

2025年實施的關稅調整為國際診斷設備、耗材和試劑採購相關人員帶來了新的挑戰。部分進口檢測設備和組件關稅的提高，對獸醫診斷實驗室、設備製造商和耗材經銷商的籌資策略帶來了成本壓力。這些財務變化迫使各機構重新評估其供應商關係、庫存策略和資本支出計劃，以減輕對短期預算的影響。

分析檢測方法、物種特異性需求、最終使用者、病原體多樣性、檢體基質和產品類型如何相互交織，以確定診斷優先事項和投資策略。

細分市場層面的趨勢揭示了不同的檢測方法、動物群、終端用戶、病原體群體、檢體基質和產品類型如何影響診斷需求和創新重點。檢測類型分類包括自動化系統、肉湯微量稀釋法、紙錠擴散法、Etest 和分子檢測方法，其中自動化系統又根據平台進一步細分，例如 MicroScan、PHOENIX、VITEK 和 WalkAway 系統。肉湯微量稀釋法分為自動化和手動兩種形式，而分子診斷方法包括 LAMP、NGS、PCR 和 qPCR，每種方法在速度、靈敏度和資訊深度之間各有優劣。

美洲、歐洲、中東和非洲以及亞太地區對診斷方法的採用情況因地區而異，這取決於基礎設施、法律規範和物種特定優先事項。

區域趨勢凸顯了地理因素、法規環境和產業基礎設施如何影響抗菌藥物敏感性檢測解決方案的採用。在美洲，先進的實驗室網路和成熟的獸醫臨床實踐支援自動化設備和整合資訊技術的早期應用。同時，區域性措施強調監測數據的總結以及將臨床實驗室與公共衛生系統連接起來的管理計畫。私人實驗室的整合，加上針對特定行業的監管關注，促使伴侶動物和牲畜領域的獸醫診斷業務獲得了大量投資。

供應商如何將檢驗的平台、現場支援和整合數據分析結合起來，以提供強大的診斷解決方案和長期的客戶夥伴關係？

獸醫抗菌藥物敏感性檢測領域的主要企業憑藉其平台廣度、地域覆蓋範圍和服務能力脫穎而出，這些優勢既能滿足常規診斷需求，也能應對複雜的監測要求。檢驗的自動化儀器與強大的試劑供應鏈和數據管理軟體結合的製造商，在支援尋求工作流程標準化的高通量實驗室方面具有優勢。同時，投資於模組化桌上型平台和專用試劑盒的公司，則能更好地滿足分散的臨床環境和物種特異性檢測需求。

為了支援管理目標，供應商和實驗室正在實施切實可行的策略措施，以提高診斷效能、供應彈性和整合資料能力。

產業領導企業應優先投資於能夠提升診斷準確性、增強供應韌性並最佳化可操作數據工作流程的項目，以滿足臨床和監測需求。首先，透過同時提供高通量自動化系統和靈活的桌上型解決方案，供應商可以根據最終用戶的實際操作情況客製化平台組合，從而適應各種實驗室環境和臨床場景。此外，配套可靠的試劑盒、試劑和品管材料能夠降低部署門檻，並確保不同地點結果的可重複性。

採用混合方法，結合專家訪談、技術文獻回顧和產品趨勢分析，得出實用且經過嚴格檢驗的診斷見解。

這項綜合分析基於多方面的調查方法，結合了質性研究、產業專家訪談、文獻綜述和產品趨勢分析，從而全面了解獸用抗菌藥物敏感性檢測環境。關鍵資訊來源包括與實驗室主任、臨床獸醫、採購負責人和行業高管進行結構化訪談，以了解營運重點、檢驗實踐和採購行為。透過這些對話，我們著重揭示實際工作流程以及實驗室在速度、準確性和成本之間權衡取捨的實際情況。

綜合診斷、彈性供應鏈和相關人員合作概括了這些因素如何定義獸醫學中合理使用抗生素和療效測試的下一階段。

總之，獸用抗菌藥物敏感性檢測正處於轉折點，其特點是技術進步、採購趨勢轉變以及對數據驅動型管理的日益成長的期望。表現型和分子方法的並存為改進臨床決策和監測提供了互補途徑，而數位整合則增強了將孤立的檢測結果轉化為長期洞察的能力。然而，與檢體多樣性、物種特異性檢驗和供應鏈脆弱性相關的挑戰仍然突出，需要製造商、檢測實驗室和政策制定者共同應對。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 獸用抗菌藥物敏感性檢測市場：依檢測類型分類

  • 自動化系統
    • 微型掃描系統
    • 鳳凰系統
    • VITEK系統
    • 離開系統
  • 肉湯微量稀釋法
    • 自動化肉湯微量稀釋法
    • 手動肉湯微量稀釋法
  • 紙錠擴散法
  • Etest
  • 分子方法
    • LAMP方法
    • NGS方法
    • PCR方法
    • 定量PCR方法

第9章 獸用抗菌藥物敏感性檢測市場：依動物類型分類

  • 水產養殖
  • 伴侶動物
  • 馬
  • 家畜
  • 家禽

第10章 獸用抗菌藥物敏感性檢測市場：依病原體類型分類

  • 真菌
  • 革蘭氏陰性菌
  • 革蘭氏陽性菌
  • 分枝桿菌

第11章 獸用抗菌藥物敏感性檢測市場：依檢體類型分類

  • 血
  • 母乳
  • 拭子
  • 組織
  • 尿

第12章 獸用抗菌藥物敏感性檢測市場：依產品類型分類

  • 裝置
    • 自動分析儀
    • 桌面設備
  • 試劑盒和試劑
    • 消耗品
    • 試劑
  • 軟體和服務
    • 資料管理軟體
    • 技術支援和諮詢

第13章 獸用抗菌藥物敏感性檢測市場：依最終用戶分類

  • 製藥和生物技術
  • 研究機構
  • 獸醫診斷實驗室
  • 獸醫醫院和診所

第14章 獸用抗菌藥物敏感性檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 獸用抗菌藥物敏感性檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 獸用抗菌藥物敏感性檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國獸用抗菌藥物敏感性檢測市場

第18章：中國獸用抗菌藥物敏感性檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accelerate Diagnostics, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • bioMerieux SA
  • Bruker Corporation
  • Creative Diagnostics
  • Eurofins Scientific SE
  • IDEXX Laboratories, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • SGS SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-FD3F12D533B4

The Veterinary Antimicrobial Susceptibility Testing Market was valued at USD 123.33 million in 2025 and is projected to grow to USD 137.71 million in 2026, with a CAGR of 9.43%, reaching USD 231.88 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 123.33 million
Estimated Year [2026] USD 137.71 million
Forecast Year [2032] USD 231.88 million
CAGR (%) 9.43%

Contextualizing veterinary antimicrobial susceptibility testing within clinical practice, laboratory operations, and the broader One Health imperative to guide timely and responsible interventions

The evolution of antimicrobial resistance in animal health demands a clear, evidence-driven introduction that frames the role of diagnostic testing in preserving therapeutic efficacy and safeguarding both animal and public health. Veterinary antimicrobial susceptibility testing operates at the intersection of clinical decision-making, surveillance, and regulatory oversight, and its effective deployment influences treatment outcomes, antimicrobial stewardship programs, and the detection of emerging resistance mechanisms. As diagnostic capabilities advance, laboratories and clinicians must adopt workflows and technologies that deliver reliable, reproducible results within clinically actionable timeframes.

The introduction to this landscape recognizes the heterogeneity of veterinary practice, from high-throughput diagnostic laboratories servicing livestock operations to point-of-care testing in companion animal clinics and aquaculture settings. Differences in species biology, sample matrices, and pathogen diversity create unique analytical challenges that require tailored methodologies and interpretive criteria. Consequently, laboratory directors and policy-makers must balance considerations of accuracy, turnaround time, cost, and regulatory compliance when selecting testing platforms and protocols.

Moreover, the integration of molecular methods alongside phenotypic assays has reshaped diagnostic pathways. Molecular approaches enable rapid detection of resistance determinants and outbreak-related genotypes, while traditional broth microdilution and disk diffusion remain the clinical standards for phenotypic susceptibility interpretation. This introduction underscores the imperative for cross-disciplinary collaboration among veterinarians, microbiologists, epidemiologists, and industry partners to translate diagnostic innovation into sustained improvements in antimicrobial stewardship and animal health outcomes.

How technological innovation, regulatory evolution, and digital integration are reshaping veterinary susceptibility testing and accelerating clinical and surveillance capabilities

Transformative shifts in veterinary antimicrobial susceptibility testing reflect technological innovation, shifting regulatory expectations, and evolving clinical needs that together are redefining diagnostic pathways. Automated systems are improving throughput and standardization, enabling laboratories to scale operations while reducing variability in susceptibility interpretation. Concurrently, rapid molecular techniques and next-generation sequencing are expanding the ability to detect resistance determinants and trace transmission, thus enhancing surveillance capacity and informing targeted interventions.

Industry adoption is further influenced by digital transformation, with data management software and integrated informatics platforms supporting interpretive consistency, reporting, and longitudinal surveillance. These tools facilitate the aggregation of susceptibility data across facilities and species, which strengthens regional and national antimicrobial stewardship initiatives. At the same time, regulatory bodies and professional societies are intensifying guidance on interpretive criteria and validation standards, prompting laboratories to re-evaluate workflows and ensure compliance with evolving quality frameworks.

Economic and operational pressures are catalyzing changes in market behavior. End users demand solutions that balance accuracy and speed with cost-effectiveness, leading to a diversification of offerings across automated instruments, bench-top systems, and modular kits. As a result, manufacturers and service providers are increasingly focused on interoperability, remote support, and tailored reagent systems that address the practical realities of veterinary testing environments. Together, these shifts are driving a more connected, responsive diagnostic ecosystem capable of supporting both clinical care and public health objectives.

Assessing the operational and procurement consequences of 2025 tariff adjustments on diagnostic equipment, consumables, and laboratory supply chain resilience

Tariff changes enacted in 2025 have introduced a new layer of complexity for stakeholders procuring diagnostic instruments, consumables, and reagents internationally. Increased duties on certain imported laboratory equipment and components have created cost pressures that affect procurement strategies for veterinary diagnostic laboratories, manufacturers of instruments, and distributors of consumables. These fiscal shifts have prompted organizations to reassess supplier relationships, inventory strategies, and capital investment timelines to mitigate near-term budgetary impacts.

In response, several laboratories and end users are prioritizing local sourcing where feasible, engaging with regional manufacturers to diversify supply chains and reduce exposure to tariff volatility. This has accelerated conversations around regional manufacturing capacity and the localization of critical consumables such as broth microdilution panels, disk diffusion supplies, and molecular assay reagents. Simultaneously, procurement teams are evaluating total cost of ownership, including logistics, customs processing, and potential delays, to inform purchasing cycles and service-level agreements.

On the supplier side, manufacturers are exploring strategic responses that include partial regional manufacturing, pricing rebates, and bundled service offerings to preserve market access. These adaptations aim to sustain adoption rates of automated systems and molecular platforms by minimizing direct cost pass-throughs to end users. Importantly, the tariff environment has highlighted the need for more robust risk assessment frameworks within laboratory procurement processes, emphasizing contingency planning and collaborative approaches that protect testing continuity while managing fiscal constraints.

Dissecting how test modalities, species-specific needs, end users, pathogen diversity, sample matrices, and product categories converge to define diagnostic priorities and investment strategies

Segment-level dynamics illuminate how different test modalities, animal populations, end users, pathogen groups, sample matrices, and product categories shape diagnostic demand and innovation priorities. Test type distinctions span Automated Systems, Broth Microdilution, Disk Diffusion, Etest, and Molecular Methods, with Automated Systems further differentiated by platforms such as MicroScan, PHOENIX, VITEK, and WalkAway systems. Broth microdilution is bifurcated into automated and manual formats, while molecular modalities encompass LAMP-based methods, NGS-based strategies, PCR, and qPCR, each offering distinct trade-offs between speed, sensitivity, and informational depth.

Animal type segmentation covers aquaculture, companion animals, equine, livestock, and poultry, highlighting how disease prevalence, husbandry practices, and regulatory frameworks vary across species and influence testing workflows. End users range from pharmaceutical and biotech companies to research institutes, veterinary diagnostic laboratories, and veterinary hospitals and clinics, and each of these stakeholders exhibits unique priorities: pharmaceutical developers emphasize standardized AST data for drug development, research institutes focus on method development and epidemiology, diagnostic laboratories prioritize throughput and quality control, and clinical settings require rapid, actionable results.

Pathogen type divides into fungi, Gram-negative bacteria, Gram-positive bacteria, and mycobacteria, which necessitates distinct panels, interpretive criteria, and containment practices. Sample types such as blood, milk, swab specimens, tissue, and urine impose diverse pre-analytical challenges that influence assay selection and validation needs. Product-type segmentation spans instruments, kits and reagents, and software and services; instruments are further categorized into automated and bench-top systems, kits and reagents into consumables and reagents, and software and services into data management software and technical support and consulting. These intersecting segments drive differential investment patterns, validation requirements, and market entry strategies, and they underscore the importance of modular product design, robust supply chains, and targeted customer support to meet the varied demands of the veterinary diagnostic community.

Regional diagnostic adoption is driven by infrastructure, regulatory frameworks, and species-specific priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Regional patterns underscore how geography, regulatory context, and industry infrastructure shape adoption of antimicrobial susceptibility testing solutions. In the Americas, advanced laboratory networks and established veterinary clinical practices support early adoption of automated instruments and integrated informatics, while regional initiatives emphasize surveillance data aggregation and stewardship programs that connect clinical laboratories with public health systems. Investment in veterinary diagnostics is visible across companion animal and livestock sectors, driven by a combination of private laboratory consolidation and sector-specific regulatory attention.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts and laboratory accreditation frameworks are generating demand for standardized testing protocols and interoperable data systems. Northern and Western European markets exhibit high uptake of molecular diagnostics and automated platforms, supported by robust surveillance infrastructures, whereas other subregions focus on capacity building and access to reliable consumables. Meanwhile, the Middle East and Africa are prioritizing scalable, cost-effective solutions that address logistical constraints and species diversity across varying husbandry systems.

Asia-Pacific remains a dynamic region with growing manufacturing capabilities and a strong emphasis on aquaculture and livestock diagnostics, reflecting the region's agricultural footprint. Rapid urbanization and rising companion animal ownership in certain markets are creating parallel demand for clinical-grade diagnostics. Across these regions, cross-border trade, regional manufacturing, and evolving regulatory requirements are prompting manufacturers and laboratories to adopt flexible distribution models and localized support strategies to ensure consistent testing quality and supply reliability.

How vendors are combining validated platforms, localized support, and integrated data analytics to deliver resilient diagnostic solutions and long-term customer partnerships

Leading organizations in the veterinary antimicrobial susceptibility testing space are differentiating through platform breadth, regional reach, and service capabilities that address both routine diagnostic needs and complex surveillance requirements. Manufacturers that combine validated automated instruments with robust reagent supply chains and data management software have an advantage in supporting high-throughput laboratories seeking to standardize workflows. At the same time, companies that invest in modular bench-top platforms and specialized kits are well positioned to serve decentralized clinical settings and species-specific testing demands.

Service and support offerings play a critical role in maintaining instrument uptime and ensuring interpretive consistency across sites. Technical support, training programs, and consulting services that assist laboratories with validation, quality assurance, and regulatory compliance enhance customer retention and create opportunities for long-term partnerships. Collaborative engagements with research institutes and pharmaceutical developers further strengthen product pipelines and phase-in of new methodologies, especially for emerging resistance mechanisms.

Strategic differentiation also extends to software and analytics capabilities. Providers that enable integrated data management, automated reporting, and trend analysis help laboratories convert raw susceptibility data into actionable intelligence for clinicians and stewardship committees. Companies leveraging partnerships to expand regional manufacturing and distribution networks are better equipped to respond to supply chain disruptions and tariff impacts, thereby preserving market access and supporting consistent testing availability for end users.

Practical strategic moves for vendors and laboratories to strengthen diagnostic performance, supply resilience, and integrated data capabilities in support of stewardship objectives

Industry leaders should prioritize investments that strengthen diagnostic accuracy, supply resilience, and actionable data workflows to meet clinical and surveillance needs. First, aligning platform portfolios with end-user operational realities-by offering both high-throughput automated systems and flexible bench-top solutions-will allow providers to serve the full spectrum of laboratory environments and clinical contexts. Complementing hardware with reliable kits, reagents, and quality control materials reduces barriers to adoption and supports reproducible results across sites.

Second, expanding regional manufacturing and logistics capabilities will mitigate exposure to tariff-related cost volatility and geopolitical supply disruptions. Establishing localized reagent production, strategic distribution partnerships, and inventory buffering strategies will protect continuity of testing services. Third, investing in data management software and interoperability increases the value proposition for end users by enabling integrated reporting, trend analysis, and data sharing for stewardship and surveillance purposes. This approach fosters stronger ties with laboratories and policy stakeholders while creating new revenue streams linked to analytics and advisory services.

Finally, industry players should deepen engagement with regulators, professional societies, and veterinary networks to align assay validation, interpretive criteria, and reporting standards. Proactive collaboration will accelerate adoption of innovative methods, ensure compliance with evolving guidelines, and support the translation of diagnostic data into effective stewardship policies. Collectively, these recommendations encourage a balanced strategy that emphasizes technological excellence, operational resilience, and stakeholder collaboration to drive sustainable outcomes.

A mixed-methods approach combining expert interviews, technical literature review, and product landscape analysis to produce actionable and rigorously validated diagnostic insights

This research synthesis draws on a multidimensional methodology that combines primary qualitative engagement with domain experts, secondary literature review, and product landscape analysis to build a comprehensive understanding of the veterinary antimicrobial susceptibility testing environment. Primary inputs include structured interviews with laboratory directors, clinical veterinarians, procurement specialists, and industry executives to capture operational priorities, validation practices, and procurement behaviors. These conversations prioritize insights into real-world workflows and the practical trade-offs laboratories make between speed, accuracy, and cost.

Secondary research canvassed peer-reviewed scientific publications, regulatory guidance documents, and public surveillance reports to ensure technical accuracy in describing methodologies, interpretive criteria, and pathogen-specific testing considerations. Product landscape analysis involved cataloging instrument platforms, assay formats, reagent systems, and software offerings to map functional capabilities and service models. Throughout, attention was paid to validation requirements, quality management practices, and the implications of regulatory frameworks across jurisdictions.

Data synthesis integrated qualitative findings with product and regional analyses to identify key trends, operational challenges, and strategic opportunities. Cross-validation of insights was achieved by triangulating perspectives from multiple stakeholder groups and by assessing consistency with documented regulatory developments and peer-reviewed evidence. This mixed-methods approach ensures that conclusions reflect practical realities and technical rigor while remaining actionable for decision-makers across industry, clinical, and policy domains.

Summarizing how integrated diagnostics, resilient supply chains, and stakeholder collaboration will define the next phase of veterinary antimicrobial stewardship and testing effectiveness

In conclusion, veterinary antimicrobial susceptibility testing is at an inflection point characterized by technological advancement, shifting procurement dynamics, and heightened expectations for data-driven stewardship. The coexistence of phenotypic and molecular approaches offers complementary pathways to improve clinical decision-making and surveillance, while digital integration enhances the ability to transform isolated test results into longitudinal intelligence. However, challenges related to sample diversity, species-specific validation, and supply chain vulnerabilities remain salient and require coordinated responses from manufacturers, laboratories, and policy-makers.

Moving forward, success will depend on pragmatic strategies that align product innovation with the operational realities of diverse veterinary settings. Strengthening regional manufacturing, enhancing technical support, and deploying interoperable software solutions will reduce friction for end users and protect testing continuity in the face of fiscal and logistical pressures. Equally important is collaborative engagement across stakeholders to harmonize validation standards and ensure that diagnostic outputs are translated into effective antimicrobial stewardship actions that protect both animal and public health.

Ultimately, the diagnostic community has an opportunity to deliver measurable improvements in treatment outcomes and resistance containment by prioritizing accuracy, accessibility, and actionable data flows. By doing so, stakeholders can help secure the long-term effectiveness of antimicrobials and support resilient animal health systems that respond efficiently to evolving microbial threats.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Antimicrobial Susceptibility Testing Market, by Test Type

  • 8.1. Automated Systems
    • 8.1.1. MicroScan Systems
    • 8.1.2. PHOENIX Systems
    • 8.1.3. VITEK Systems
    • 8.1.4. WalkAway Systems
  • 8.2. Broth Microdilution
    • 8.2.1. Automated Broth Microdilution
    • 8.2.2. Manual Broth Microdilution
  • 8.3. Disk Diffusion
  • 8.4. Etest
  • 8.5. Molecular Methods
    • 8.5.1. LAMP-Based Methods
    • 8.5.2. NGS-Based Methods
    • 8.5.3. PCR-Based Methods
    • 8.5.4. QPCR-Based Methods

9. Veterinary Antimicrobial Susceptibility Testing Market, by Animal Type

  • 9.1. Aquaculture
  • 9.2. Companion Animals
  • 9.3. Equine
  • 9.4. Livestock
  • 9.5. Poultry

10. Veterinary Antimicrobial Susceptibility Testing Market, by Pathogen Type

  • 10.1. Fungi
  • 10.2. Gram-Negative Bacteria
  • 10.3. Gram-Positive Bacteria
  • 10.4. Mycobacteria

11. Veterinary Antimicrobial Susceptibility Testing Market, by Sample Type

  • 11.1. Blood
  • 11.2. Milk
  • 11.3. Swab
  • 11.4. Tissue
  • 11.5. Urine

12. Veterinary Antimicrobial Susceptibility Testing Market, by Product Type

  • 12.1. Instruments
    • 12.1.1. Automated Instruments
    • 12.1.2. Bench-Top Instruments
  • 12.2. Kits And Reagents
    • 12.2.1. Consumables
    • 12.2.2. Reagents
  • 12.3. Software And Services
    • 12.3.1. Data Management Software
    • 12.3.2. Technical Support And Consulting

13. Veterinary Antimicrobial Susceptibility Testing Market, by End User

  • 13.1. Pharma And Biotech
  • 13.2. Research Institutes
  • 13.3. Veterinary Diagnostic Laboratories
  • 13.4. Veterinary Hospitals And Clinics

14. Veterinary Antimicrobial Susceptibility Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Antimicrobial Susceptibility Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Antimicrobial Susceptibility Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Veterinary Antimicrobial Susceptibility Testing Market

18. China Veterinary Antimicrobial Susceptibility Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accelerate Diagnostics, Inc.
  • 19.6. Becton, Dickinson and Company
  • 19.7. Bio-Rad Laboratories
  • 19.8. bioMerieux SA
  • 19.9. Bruker Corporation
  • 19.10. Creative Diagnostics
  • 19.11. Eurofins Scientific SE
  • 19.12. IDEXX Laboratories, Inc.
  • 19.13. Merck & Co., Inc.
  • 19.14. Neogen Corporation
  • 19.15. SGS SA
  • 19.16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALKAWAY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED BROTH MICRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL BROTH MICRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LAMP-BASED METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NGS-BASED METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PCR-BASED METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QPCR-BASED METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MILK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH-TOP INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNICAL SUPPORT AND CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNICAL SUPPORT AND CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNICAL SUPPORT AND CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMA AND BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS AND REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN VETERINARY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)

TA